# US 2026/0216344 A1 · ALC1 Inhibitors and Synergy with PARPi

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216344 A1
- Document ID: US20260216344A1
- Status: Published application
- Kind: A1
- Application number: 19/284,162
- Filed: 2025-07-29
- Published: 2026-07-30
- Earliest claimed: 2020-12-03
- Assignees: Eisbach Bio GmbH
- Applicants: Eisbach Bio GmbH
- Inventors: William M. Menzer; Gunnar Knobloch; Corinna Lieleg; Adrian Schomburg; Andreas Ladurner; Peter Sennhenn
- Web page: https://patentgrep.com/patent/US20260216344A1

## CPC

- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- C07D 495/04: Ortho-condensed systems
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 35/00: Antineoplastic agents
- C07D 495/14: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to small molecule compounds that allosterically inhibit ALC1 (CHD1L) and which induce the trapping of PARP1, PARP2 and/or PARP3 on chromatin or at DNA damage sites. Disruption of the chromatin remodeling forces of ALC1 through these agents enables a highly selective therapy for targeting the DNA damage functions of PARP enzymes in several proliferative diseases, notably BRCA-deficient cancers. Via inhibition of the enzymatic activity, the compounds engage the synthetic lethality between BRCA1/2 and ALC1. By trapping PARP enzymes, inhibitors of ALC1 potentiate the cancer cell killing properties of PARP inhibitors, enable therapeutic approaches where ALC1 is amplified as an oncogene, therapeutically make it possible to overcome PARP inhibitor resistance mechanisms and enable an alternative approach to the treatment of germline or acquired BRCA1/BRCA2 deficiency, including tumors defined by “BRCAness” or other changes in DNA repair networks.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

An allosteric inhibitor of Chromodomain-helicase-DNA-binding protein 1-like (ALC1), wherein the allosteric inhibitor has a structure selected of formula (VII):
wherein Q is H or OH; and
isomers, salts, solvates, chemically protected forms, and prodrugs thereof.

### Claim 17 (depends on 16)

A pharmaceutical composition comprising the allosteric inhibitor of ALC1 (ALC1i) of claim 16 and a pharmaceutically acceptable excipient.

### Claim 18 (depends on 16)

A method for treating or ameliorating a proliferative disease in a patient, wherein the method comprises the administration of the ALC1i of claim 16.

### Claim 19 (depends on 16)

A method of treating or ameliorating a proliferative disease in a patient, wherein the method comprises the administration of a PARPi and the administration of the ALC1i of claim 16.

### Claim 20 (depends on 19)

The method of claim 19, wherein the PARPi lowers PARP activity and/or inhibits PARP1, PARP2 and/or PARP3, preferably PARP2 on chromatin, wherein preferably the PARPi
(i) that lowers PARP activity is selected from small interfering RNA, and
(ii) that inhibits PARP1 is selected from the group consisting of a compound of
(a) formula (II)
and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein:
A and B together represent an optionally substituted, fused aromatic ring;
X is NRX or CRXRY;
if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1;
RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups;
RY is selected from H, hydroxy, amino;
or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group;
RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and
R1 is selected from H and halo;
and
(b) formula (III)
and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein:
Y and Z are each independently selected from the group consisting of:
1. an aryl group optionally substituted with 1, 2, or 3 R6;
2. a heteroaryl group optionally substituted with 1, 2, or 3 R6;
3. a substituent independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkylene, oxo, heterocycloalkyl, heterocycloalkylalkyl, alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, (RARB)alkylene, (NRARB)carbonyl, (NRARB)carbonylalkylene, (NRARB)sulfonyl, and (RARB)sulfonylalkylene;
wherein each R6 is selected from OH, NO2, CN, Br, Cl, F, I, C1-6-alkyl, C3-8-cycloalkyl, C2-8-heterocycloalkyl; C2-6-alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, C2-6-alkynyl, aryl, arylalkyl, C3-8-cycloalkylalkyl, haloalkoxy, haloalkyl, hydroxyalkylene, oxo, heteroaryl, heteroarylalkoxy, heteroaryloxy, heteroarylthio, heteroarylalkylthio, heterocycloalkoxy, C2-8-heterocycloalkylthio, heterocyclooxy, heterocyclothio, NRARB, (RARB)C1-6-alkylene, (NRARB)carbonyl, (RARB)carbonylalkylene, (NRARB)sulfonyl, and (NRARB)sulfonylalkylene;
R1, R2, and R3 are each independently selected from the group consisting of hydrogen, halogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, cycloalkyl, alkynyl, cyano, haloalkoxy, haloalkyl, hydroxyl, hydroxyalkylene, nitro, NRARB, NRARB alkylene, and (RARB)carbonyl;
A and B are each independently selected from hydrogen, Br, Cl, F, I, OH, C1-6-alkyl, C3-8-cycloalkyl, alkoxy, alkoxyalkyl wherein C1-6-alkyl, C3-8-cycloalkyl, alkoxy, alkoxyalkyl are optionally substituted with at least one substituent selected from OH, NO2, CN, Br, Cl, F, I, C1-6-alkyl, and C3-8-cycloalkyl, wherein B is not OH;
RA, and RB are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, and alkylcarbonyl; or RA and RB taken together with the atom to which they are attached form a 3-10 membered heterocycle ring optionally having one to three heteroatoms or hetero functionalities selected from the group consisting
of —O—, —NH, —N(C1-6-alkyl)-, —NCO(C1-6-alkyl)-, —N(aryl)-, —N(aryl-C1-6-alkyl-), —N(substituted-aryl-C1-6-alkyl-)—, —N(heteroaryl)-, —N(heteroaryl-C1-C6-alkyl-)-, —N(substituted-heteroaryl-C1-6 alkyl-)—, and —S— or S(O)q-, wherein q is 1 or 2 and the 3-10 membered heterocycle ring is optionally substituted with one or more substituents;
R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxyalkyl, haloalkyl, hydroxyalkylene, and (NRARB)alkylene; and isomers, salts, solvates, chemically protected forms, and prodrugs thereof;
(iii) that inhibits PARP1 and PARP2 is selected from the group consisting of a compound of
(a) formula (IV)
and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein:
R1 is hydrogen or fluorine; and
R2 is hydrogen or fluorine;
and
(b) formula (V)
and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein:
R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB, and (NRARB)carbonyl;
A is a nonaromatic 4, 5, 6, 7, or 8-membered ring that contains 1 or 2 nitrogen atoms and, optionally, one sulfur or oxygen atom, wherein the nonaromatic ring is optionally substituted with 1, 2, or 3 substituents selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, cyano, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, heteroaryl, heteroarylalkyl, hydroxy, hydroxyalkyl, nitro, NRCRD, (NRCRD)alkyl, (NRCRD)carbonyl, (NRCRD)carbonylalkyl, and (NRCRD)sulfonyl; and
RA, RB, RC, and RD are independently selected from the group consisting of hydrogen, alkyl, and alkycarbonyl
(iii) that inhibits PARP1, PARP2 and PARP3 is a compound of formula (VI)
and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein:
R1 is: H; halogen; cyano; an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group (e.g., unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, and amino, alkoxy, alkyl, and aryl groups unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, carboxy, and optionally substituted amino and ether groups (such as O-aryl)); or —C(O)—R10, where R10 is: H; an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group (e.g., unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, amino, and alkyl and aryl groups unsubstituted or substituted with one or more substituents selected from halo, hydroxy, nitro, and amino); or OR100 or NR100R110, where R100 and R110 are each independently H or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group (e.g., unsubstituted or substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, amino, and alkyl and aryl groups unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, and optionally substituted amino groups);
R2 is H or alkyl;
R3 is H or alkyl;
R4 is H, halogen or alkyl;
X is O or S;
Y is (CR5R6)(CR7R8) n or N—C(R5), where:
n is 0 or 1;
R5 and R6 are each independently H or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group (e.g., unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, amino, and lower alkyl, lower alkoxy, or aryl groups unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, and amino); and
R7 and R5 are each independently H or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group (e.g., unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, amino, and lower alkyl, lower alkoxy, and aryl groups unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, nitro, and amino);
where when R1, R4, R5, R6, and R7 are each H, R8 is not unsubstituted phenyl.

### Claim 21 (depends on 20)

The method of claim 20, wherein the PARPi is selected from the group consisting of Olaparib, Talazoparib, Niraparib, Rucaparib, and Veliparib, in particular of Veliparib, Olaparib, and Talazoparib.

### Claim 22 (depends on 18)

The method of claim 18, wherein the proliferative disease is selected from a HRD tumor, a BRCA-1 and/or BRCA-2-deficient tumor, and a tumor in which expression of PARP-1, PARP-2, PARP-3 and/or ALC1 is increased in comparison to non-tumor cells, and/or wherein the proliferative disease is selected from hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, colorectal cancer.

### Claim 23 (depends on 19)

The method of claim 19, wherein the PARPi and ALC1i are administered concomitantly or separately.

### Claim 24 (depends on 16)

A kit of parts comprising separately packaged a PARPi and the ALC1i of claim 16; or a composition comprising a PARPi and the ALC1i of claim 16.

### Claim 25 (depends on 16)

The allosteric inhibitor of ALC1 of claim 16 having the structure:
and isomers, salts, solvates, chemically protected forms, and prodrugs thereof.

### Claim 26 (depends on 16)

The allosteric inhibitor of ALC1 of claim 16 having the structure:
and isomers, salts, solvates, chemically protected forms, and prodrugs thereof.
